Trial results for Empagliflozin in combination with finerenone were posted on 2026-07-13, demonstrating a least squares mean ratio of 0.483 for urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline in participants with chronic kidney disease and type 2 diabetes. This combination therapy showed a greater reduction in UACR compared to either agent alone.

Background

Empagliflozin is a medication that lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. Finerenone works by blocking a group of proteins called mineralocorticoid receptors. Increased stimulation of these receptors is known to trigger injury and inflammation in the kidney, suggesting a role in chronic kidney disease (CKD).

Trial design

The study, identified as NCT05254002, was a PHASE2 trial that enrolled 1664 participants. It focused on adult participants with Type 2 Diabetes Mellitus and Chronic Kidney Disease. The interventions included finerenone (10 mg or 20 mg), empagliflozin, empagliflozin placebo, and finerenone placebo. The study aimed to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of participants' kidney function compared to either treatment alone, primarily by assessing the level of protein in the urine.

Key results

At Day 180, the least squares mean ratio of UACR relative to baseline for the combination of finerenone and empagliflozin was 0.483. In comparison, the least squares mean ratio for empagliflozin alone (with finerenone placebo) was 0.708, and for finerenone alone (with empagliflozin placebo) was 0.683. The number of participants showing a relative change in UACR category at Day 180 (e.g., >30%, >40%, >50%) was 168 Participants in the finerenone and empagliflozin group, compared to 123 Participants in the finerenone and empagliflozin placebo group.

What this means

The results suggest that the combination of empagliflozin and finerenone may offer enhanced benefits in reducing urinary albumin-to-creatinine ratio (UACR) in patients with chronic kidney disease and type 2 diabetes, compared to either drug administered as monotherapy. This finding from a PHASE2 trial indicates a potential for improved kidney protection and warrants further investigation in larger clinical studies.

Source

This information was sourced from ClinicalTrials.gov, documenting the trial results for study NCT05254002 on 2026-07-13. The study details are available on clinicaltrials.gov.